Circulating white blood cell traits and colorectal cancer

risk: A Mendelian randomization study 2

- Andrei-Emil Constantinescu^{1,2,3*}, Caroline J Bull^{1,2,3}, Nicholas Jones⁴, Ruth Mitchell^{1,2}, 3
- Kimberley Burrows^{1,2}, Niki Dimou⁵, Stéphane Bézieau⁶, Hermann Brenner^{7,8,9}, Daniel D Buchanan^{10,110,12}, Mauro D'Amato^{13,14,15}, Mark A Jenkins¹⁶, Victor Moreno^{17,18,19,20}, Rish K
- Pai²¹, Caroline Y Um²², Emily White^{4,24}, Neil Murphy⁵, Marc Gunter⁵, Nicholas J Timpson^{1,2}
- Jeroen R Huyghe^{22§} and Emma E Vincent^{1,2,3§} 7
- ¹MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK 9
- ²Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK 10
- ³School of Translational Health Sciences, Bristol Medical School, University of Bristol, 11
- Bristol, United Kingdom 12
- ⁴Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom 13
- ⁵Nutrition and Metabolism Branch, International Agency for Research on Cancer, World 14
- Health Organization, Lyon, France
- 16 ⁶Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) Nantes, Nantes,
- 17 France

8

- ⁷Division of Clinical Epidemiology and Aging Research, German Cancer Research Center 18
- (DKFZ), Heidelberg, Germany 19
- ⁸Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National 20
- Center for Tumor Diseases (NCT), Heidelberg, Germany 21
- ⁹German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 22
- Heidelberg, Germany 23
- ¹⁰Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of 24
- Melbourne, Parkville, Victoria 3010 Australia 25
- ¹¹University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer 26
- 27 Centre, Parkville, Victoria 3010 Australia
- ¹²Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, 28
- Victoria, Australia
- ¹³Department of Medicine and Surgery, LUM University, Casamassima, Italy 30
- ¹⁴Gastrointestinal Genetics Lab, CIC bioGUNE BRTA, Derio, Spain 31
- ¹⁵Ikerbasque, Basque Foundation for Science, Bilbao, Spain 32
- ¹⁶Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global 33
- Health, The University of Melbourne, Melbourne, Victoria, Australia 34

- 35 ¹⁷Oncology Data Analytics Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet
- 36 de Llobregat, Barcelona, Spain
- 37 ¹⁸CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- 38 ¹⁹Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona,
- 39 Spain
- 40 ²⁰ONCOBEL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de
- 41 Llobregat, Barcelona, Spain
- 42 ²¹Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale,
- 43 Arizona, USA
- 44 ²²Department of Population Science, American Cancer Society, Atlanta, Georgia, USA
- 45 ²³Department of Epidemiology, University of Washington School of Public Health, Seattle,
- 46 Washington, USA
- 47 ²⁴Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington,
- 48 USA

- 49 §These authors contributed equally.
- **Corresponding author:
- 51 Andrei-Emil Constantinescu, Oakfield House, Oakfield Grove, Bristol, United Kingdom,
- 52 BS8 2BN, +44 (0) 117 928 7274, andrei.constantinescu@bristol.ac.uk

Abstract

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

Observational studies have suggested a protective role for eosinophils in colorectal cancer (CRC) development and implicated neutrophils, but the causal relationships remain unclear. Here, we aimed to estimate the causal effect of circulating white blood cell (WBC) counts (N = ~550,000) for basophils, eosinophils, monocytes, lymphocytes and neutrophils on CRC risk (N = 52,775 cases and 45,940 controls) using Mendelian randomization (MR). For comparison, we also examined this relationship using individual-level data from UK Biobank (4,043 incident CRC cases and 332,773 controls) in a longitudinal cohort analysis. The inverse-variance weighted (IVW) MR analysis suggested a protective effect of increased basophil count and eosinophil count on CRC risk [OR per 1-SD increase: 0.88, CI(95%): 0.78-0.99, P=0.04; OR: 0.93, CI(95%): 0.88-0.98, P=0.01]. The protective effect of eosinophils remained [OR per 1-SD increase: 0.88, CI(95%): 0.80-0.97, P=0.01] following adjustments for all other WBC subtypes, to account for genetic correlation between the traits, using multivariable MR. A protective effect of increased lymphocyte count on CRC risk was also found [OR: 0.84, CI(95%): 0.76-0.93, P=6.70e-4] following adjustment. Consistent with MR results, a protective effect for eosinophils in the cohort analysis in the fully adjusted model [RR per 1-SD increase: 0.96, CI(95%): 0.93-0.99, P=0.02] and following adjustment for the other WBC subtypes [RR: 0.96, CI(95%): 0.93-0.99, P=0.001] was observed. Our study implicates peripheral blood immune cells, in particular eosinophils and lymphocytes, in CRC development, highlighting a need for mechanistic studies to interrogate these relationships.

What is already known of this topic – While previous observational studies have suggested a protective role for eosinophils in colorectal cancer development and implicated neutrophils,

79

83

84

85

86

87

88

89

90

91

93

94

95

96

97

98

whether changes in the levels of circulating white blood cells causes colorectal cancer has not been explored. What this study adds - Our study is the first to use Mendelian randomization (MR) to 80 81 investigate this relationship. In parallel, for comparison, we also conduct the largest cohort 82 study to date on the topic. We found evidence to suggest that elevated eosinophil and lymphocyte count may have a protective effect on CRC risk, adding new insights into the pathogenesis of CRC. How this study might affect research, practice or policy – Our findings will encourage further mechanistic exploration to understand the biological mechanisms underpinning our findings, which may lead to new therapeutic approaches or risk reduction strategies. **Keywords** Mendelian randomization, UK Biobank, Colorectal cancer, GWAS, White blood cell count, 92 Eosinophils Introduction Colorectal cancer (CRC) accounts for over 10% of all worldwide cancer cases and is the second leading cause of cancer-related deaths globally [1–3]. Overall, the number of CRC cases is rising [4] and is alarmingly on the rise in younger people (aged <50 years) [5–7]. Given current challenges, and the estimation that 50% of CRC cases may be preventable [8],

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

a focus on identifying novel risk factors, and subsequent prophylactic and treatment options is warranted to limit the future healthcare burden. White blood cells (WBCs) are commonly measured in routine blood tests and are divided into five subtypes: basophils, eosinophils, lymphocytes, monocytes and neutrophils [9]. Alterations to circulating WBC counts, have been found to play a role in disease risk, severity, and progression, CRC development and mortality [10–15]. For example, higher circulating counts of basophils and eosinophils, cells with a role in IgE-mediated immunity, have been associated with reduced CRC risk and increased survival [16-20]. Higher absolute lymphocyte count [such as T, B and natural killer (NK) cells] has also been associated with better overall survival of CRC [21,22]. By contrast, a high absolute monocyte count was found to be associated with worse CRC survival [21,22], consistent with their potential role in tumour progression and metastasis [23]. Finally, neutrophils, a critical part of the innate immune system [24], have also been associated with poor CRC overall survival [21,22]. Traditional (i.e. cross-sectional, case-control or cohort) studies account for the majority of epidemiologic analyses undertaken on CRC, which can suffer from certain limitations, such

Traditional (i.e. cross-sectional, case-control or cohort) studies account for the majority of epidemiologic analyses undertaken on CRC, which can suffer from certain limitations, such as confounding and reverse causation which can bias effect estimates [25,26]. Mendelian randomization (MR) is a method in genetic epidemiology which could overcome these issues by using single-nucleotide polymorphisms (SNPs) to proxy for an exposure of interest to estimate the effect of an exposure on an outcome [27,28]. It operates akin to a randomized control trial (RCT), as alleles are randomly assigned at birth [29]. We have used MR to estimate the total effect of each WBC trait on CRC [30], and, to account for corelation

between WBC traits, multivariable (MV) MR to estimate the direct effect of these exposures

on CRC by adjusting for their shared genetic architecture [30].

relationship between circulating WBC counts and CRC development.

In this study we aimed to investigate the relationship between circulating WBC subtypes and CRC incidence. Firstly, an MR analysis was undertaken using the most comprehensive genome-wide association study (GWAS) for both WBC subtype counts and incident CRC available. Secondly, for comparison, we ran the largest longitudinal cohort study between WBCs and CRC to date using UK Biobank. Together these analyses allow us to compare between genetically proxied and observational estimates to thoroughly explore the

Methods

Study design

We aimed to investigate the relationship between circulating WBCs and CRC using a genetic epidemiologic and complementary observational approach. First, MR analyses were undertaken to estimate the effect of WBC subtype counts on CRC. We then performed a multivariable MR (MVMR) analysis where the direct effect of each WBC subtype count was estimated by adding all five WBC subtypes into the model (Figure 1A). STROBE-MR guidelines were followed (STROBE-MR Supplement) [31]. Here, units were interpreted as odds ratio (OR) for CRC per a normalized standard deviation (1-SD) increase in WBC count. Next, a prospective longitudinal cohort study was undertaken using UK Biobank individual-level data. Here, subtype specific WBC counts were studied individually, and then each was adjusted for each of the other traits (Figure 1B). STROBE guidelines were followed

(STROBE Supplement). Here, units were interpreted as risk ratio (RR) for CRC per a normalized standard deviation (1-SD) increase in WBC count.




Figure 1. Study design. We triangulated findings from two study designs: a Mendelian randomization analysis(A) and a longitudinal cohort analysis (B) to estimate the casual effect

http://dx.doi.org/10.1136/gutjnl-2020-321534); *UK Blobank (https://doi.org/10.1038/s41586-018-0579-z)

WBC count GWAS data

of WBC on CRC risk.

Summary statistics for WBC subtype counts were obtained from the "Blood Cell Consortium" (BCX) meta-analysis, the largest study being UKBB (N=~562,243) [32]. Genetic sex, age, age², study-specific covariates and PCs 1 to 10 were used as covariates. A brief description of each study included in the meta-analysis is available in **Supplementary Table 1**. Only variants which did not display heterogenous effect across studies were selected. Specific details on QC steps and association testing are available in the source

manuscripts. Summary statistics for WBC counts were downloaded from: http://www.mhi-

humangenetics.org/en/resources/.

CRC GWAS data

GWAS summary statistics for overall CRC risk and by anatomical subsite were taken from the most comprehensive meta-analyses to date [33]: colon cancer (split into proximal and distal colon cancer) and rectal cancer. Sixty-six studies, which include those of the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), Colorectal Cancer Transdisciplinary Study (CORECT), and Colon Cancer Family Registry (CCFR) consortia were meta-analysed [34–36]. The final sample was predominantly of European ancestry with 5.36% of East Asian ancestry. These were included due to their similar genetic architecture with regards to CRC risk [37]. Genetic sex, age, study-specific variables and PCs were used as covariates. An overview of all consortia included in the CRC meta-analysis is available in Supplementary Table 2, and a breakdown of the sample sizes for each set of CRC summary statistics is presented in Supplementary Table 3.

Genetic data processing

To select valid MR instruments, summary statistics for exposures were processed using the "TwoSampleMR" R package [38,39]. The presence of correlated instruments, i.e. those in linkage disequilibrium (LD), can bias MR estimates [40]. Therefore, the exposure SNPs were clumped (r²=0.001, window=10Mb, P-value threshold=5e-8) using the 1000 Genomes European dataset [41] as a reference panel. Following this step, the exposure and outcome datasets were "harmonised" i.e. had their effect alleles placed on the same reference strand [42]. SNPs with incorrect but unambiguous strand references were corrected, while those

with ambiguous strand references were removed. Similarly, palindromic SNPs with inferable strands were kept.

MR analysis of WBC counts on CRC risk

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

Primary MR analyses were undertaken using the inverse-variance weighted (IVW) method, which is the fixed-effects meta-analysis of the estimated effect of all exposure SNPs on the CRC outcome [43]. Conditional F-statistics were calculated to detect weak instrument bias [44] for each exposure SNP as previously described [45]. Several sensitivity analyses were undertaken to compare with the main IVW estimates. The presence of vertical pleiotropy i.e. when a trait is downstream of the genetic variant but on the same biological pathway as the exposure [46], was measured using Cochran's Q heterogeneity test [47]. Horizontal pleiotropy, when some or all instruments for a trait acts through a different pathway to the exposure [46], can violate one of the main MR assumptions. A number of sensitivity MR analyses were undertaken to identify horizontal pleiotropy: MR-Egger (where the regression intercept is not constrained to zero) [48], Weighted median (the median of all SNP ratio estimates, where each ratio is weighted by the inverse of the variance) [49], Weighted mode (assumes that the most frequent estimate in a set of instruments is zero) [50] and MR-PRESSO (detects individual SNPs contributing to horizontal pleiotropy) [51]. The direction of the causal relationship between WBC traits and CRC risk was tested using the MR Steiger method, which uses Steiger's test to test the difference between the Pearson correlations of genetic variants with both the exposure and outcome [39].

Multivariable MR analysis of WBC counts on CRC risk

The IVW method was used for the MVMR analysis. First, a pair-wise analysis between all five WBC subtype counts was undertaken, where the proportion of variance explained (PVE)

for SNPs used to instrument a WBC trait was estimated in the other four WBC subtypes using previously described methodology [45]. The direct effect of each WBC subtype was estimated by adding in all five WBC subtypes into the MVMR model. Bias arising from weak instruments was also determined here. This was undertaken using methodology described by Sanderson et al., where a generalized version of Cochran's Q was employed to evaluate instrument strength [52]. Standard Cochran's Q statistic [47] was calculated to detect the presence of heterogeneity. For those traits with an F-statistic <10, a follow-up MVMR analysis was done accounting for the presence of weak instruments.

UK Biobank phenotypic data

Between the years of 2007 and 2010, UKBB participants visited assessment centres (N=22) throughout the UK [53,54]. The individuals had their health records linked, their genomes sequenced, and underwent multiple evaluations, such as self-report questionnaires and medical examinations [53,54]. The latter includes the analysis of blood cell samples using Beckman Coulter LH750 instruments designed for high throughput screening [55]. Total WBC count and WBC subtype percentage (%) were measured, with absolute WBC subtype count derived as "WBC subtype % / 100 x total WBC" and expressed as 10⁹ cells/Litre [55]. The blood sampling date variable was split into year, month, day, and minutes (passed since the start of the day of the appointment visit). Additional variables were gathered including recruitment centre, sampling device ID, age, genetic sex, principal components 1 to 10, BMI, Townsend deprivation index, smoking and alcohol drinker status (self-report questionnaire – UKBB codes 20116 and 20117). CRC cases were identified through hospital inpatient records coded to the 10th version of the International Classification of Disease (ICD-10).

Filtering and selection criteria

The UKBB dataset underwent a series of steps prior to further analyses. Withdrawn participants and those of non-European ancestry were excluded. Viable controls and incident CRC cases were defined using methodology previously described by Burrows et al. [56] (Supplementary Table 4). Here, we defined incident CRC cases as those diagnosed at least one year after blood sampling. Participants with no WBC measurement data or sampling date were removed, as were those who were known to be pregnant, have chronic conditions (e.g. HIV, blood cancers, thalassaemia), or undergoing erythropoietin treatment, as in Astle et al. [57] and Chen et al. [32], given the effects of these traits on WBC measurements. Those with acute conditions (e.g. upper respiratory infections) diagnosed less than 3 months prior to blood sampling were excluded. Finally, missing values in "Townsend Deprivation Index", "Body mass index", "Smoking status" and "Alcohol drinker status" variables were removed.

Cohort study between WBC count and CRC

We conducted a cohort analysis between circulating WBCs and incident CRC. WBC count values were log-transformed, after which they were adjusted for the following covariates: assessment centre, sex, age, age², PCs 1 to 10, as in the Chen et al. GWAS [32]. The resulting residuals were rank-inverse normal transformed and then used in a logistic regression on CRC incidence. This main observational analysis was termed "Model 1", a minimally adjusted model. An additional fully adjusted analysis was undertaken, termed "Model 2", where BMI, Townsend DI, smoker status and alcohol drinker status were added as additional covariates. Following this, another pair of analyses was run, where all five WBC subtype counts were added together into the model to reduce potential bias due to their correlated values. Analyses where each WBC trait was studied individually were termed as "univariable", while those where they were added together were termed as "multivariable".

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

Working environment All analyses were performed with R version 4.1.2 (Bird Hippie) in a Linux environment supported by the University of Bristol's Advanced Computing Research Centre (ACRC). Genetic data preparation, as well as the MR analyses, were undertaken with the "TwoSampleMR" R package [38,39]. The MVMR analyses were undertaken with the "MVMR" R package [58]. Scripts associated with this study are available on GitHub: https://github.com/andrewcon/wbc-crc. **Results** Effect of WBC count on CRC Before performing the MR analysis, the average F-statistic for each WBC trait was estimated to detect the presence of weak instrument bias, which is generally indicated by an average Fstatistic < 10 [44]. For overall CRC, these were 64.48 (basophil count, 171 SNPs), 124.72 (eosinophil count, 396 SNPs), 105.85 (lymphocyte count, 444 SNPs), 147.44 (monocyte count, 477 SNPs), 98.84 (neutrophil count, 387 SNPs), indicating strong MR instruments (Supplementary Table 5). The IVW method showed evidence of a protective effect of basophil count (1-SD increase in WBC count OR: 0.88, 95% CI: 0.78-0.99, P-value: 0.037) for CRC risk (Figure 2, Supplementary Figure 1). For eosinophil count, the IVW method showed evidence of a protective effect for CRC risk (OR: 0.93, 95% CI: 0.88-0.98, P-value: 0.012) (Figure 2, Supplementary Figure 1). These results were confirmed by the MR-Egger, weighted median and MR-PRESSO sensitivity methods (Supplementary Table 6). The IVW method

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

also showed a protective effect of eosinophil count for CRC risk (OR: 0.91, 95% CI: 0.85-0.99, P-value: 0.021) in females. All results, including those for sex- and site-specific CRC, are available in **Supplementary Table 6.** In site specific CRC analyses, the univariable IVW method demonstrated evidence for a protective effect of basophil count on colon (OR: 0.85, 95% CI: 0.74-0.98, P-value: 0.022) and distal colon (OR: 0.82, 95% CI: 0.70-0.97, P-value: 0.019) cancer (Supplementary **Table 6**). For eosinophil count, the main IVW analysis provided evidence for a protective effect for colon (OR: 0.90, 95% CI: 0.84-0.96, P-value: 0.001), proximal colon (OR: 0.89, 95% CI: 0.82-0.96, P-value: 0.003) and distal colon (OR: 0.89, 95% CI: 0.82-0.97, P-value: 0.007) cancer (Supplementary Table 6). These results were mostly supported by sensitivity analyses. There was a protective effect of total WBC count on colon (OR: 0.91, 95% CI: 0.85-0.99, P-value: 0.02) and proximal colon (OR: 0.90, 95% CI: 0.82-0.98, P-value: 0.015) cancer (Supplementary Table 6). Next, the presence of vertical and horizontal pleiotropy in the MR analyses was analysed. Cochran's heterogeneity test indicated the presence of heterogeneity in all but one WBC trait-CRC pair (basophil count-male CRC, P_{HET}=0.104) (**Supplementary Table 7**). Following this, the MR-Egger test for horizontal pleiotropy was performed. Here, evidence for this type of pleiotropy was identified for eosinophil count and colon (P_{PLT}=0.018), distal colon $(P_{PLT}=0.015)$, female $(P_{PLT}=0.049)$, male $(P_{PLT}=0.041)$ and overall $(P_{PLT}=0.015)$ CRC risk, suggesting a possible bias of MR estimates. This was also the case for lymphocyte count in female CRC (P_{PLT}=0.016) (**Supplementary Table 7**). Although the MR-PRESSO method identified the presence of SNP horizontal-pleiotropic outliers, there was little evidence that

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

the removal of these outliers contributed to a notable shift in the point estimates (Supplementary Table 8). Multivariable MR of WBC count on CRC A pair-wise analysis of the proportion of variance explained (PVE) for SNPs instrumenting each WBC trait indicated a low PVE for each of the other WBC traits, with the exception of basophil count (2.44% vs. 2.39% when instrumenting neutrophil count) (Supplementary **Table 9**). The overall results indicated that statistical power should not suffer to a large degree by adding all five WBC subtype counts into the MVMR analysis. Here, the MVMR IVW method estimated a protective effect of eosinophil count (OR: 0.88, 95% CI: 0.80-0.97, P-value: 0.011) and lymphocyte count (OR: 0.84, 95% CI: 0.76-0.93, P-value: 0.0007) on CRC risk (Figure 2). Regarding sex-specific estimates, eosinophil count was protective for CRC risk (OR: 0.83, 95% CI: 0.73-0.94, P-value: 0.004) in females, this was also the case for lymphocyte count (OR: 0.76, 95% CI: 0.67-0.87, P-value: 6.46E-05). Eosinophil count was estimated to have a direct protective effect on colon (OR: 0.84, 95% CI: 0.75-0.94, P-value: 0.002), proximal colon (OR: 0.92, 95% CI: 0.85-1.00, P-value: 0.042) and distal colon (OR: 0.88, 95% CI: 0.74-1.00, P-value: 0.049) cancer (Supplementary **Table 10**). Lymphocyte count was estimated to have a direct protective effect on colon (OR: 0.85, 95% CI: 0.76-0.96, P-value: 0.007), distal colon (OR: 0.77, 95% CI: 0.67-0.88, P-value: 0.0001) and rectal (OR: 0.86, 95% CI: 0.75-0.98, P-value: 0.022) cancer anatomical subsites (Supplementary Table 10). Sensitivity analyses were undertaken to assess heterogeneity and the presence of weak instruments in the MVMR analysis. There was evidence of heterogeneity in all WBC traitCRC pairs (**Supplementary Table 11**). Conditional F-statistics showed evidence of weak instruments (F<10) for basophil count (**Supplementary Table 11**). Based on these results, an additional MVMR analysis was run adjusting for weak instruments for basophil count (overall CRC OR_{Weak}: 1.3; male CRC OR_{Weak}: 1.2; female CRC OR_{Weak}: 1.7; colon cancer OR_{Weak}: 1.5; proximal colon cancer OR_{Weak}: 1.5; distal colon cancer OR_{Weak}: 1.5; rectal cancer OR_{Weak}: 1.6) on CRC risk (**Supplementary Table 11**).

Cohort observational analysis between WBC count and CRC

336,816 UKBB participants remained after passing filtering and selection criteria (Supplementary Figure 2). Of these, 332,773 were controls and 4,043 were incident CRC cases. When split by genetic sex, there were 154,629 male and 178,144 female controls and 2,316 male and 1,727 female cases. Those with CRC were more likely to be male (57% vs. 46%), had a higher average age (60.7 vs. 55.8 years), slightly higher BMI (28.0 vs. 27.4 kg/m²) and were more likely to have been cigarette smokers in the past (46% vs. 55% never smokers and 44% vs. 34% pervious smokers) (Table 1).

Characteristic	Control, N = 332,773 ¹	Case, N = 4,043 ¹
Sex		
Female	178,144 / 332,773 (54%)	1,727 / 4,043 (43%)
Male	154,629 / 332,773 (46%)	2,316 / 4,043 (57%)
Age (years)	55.8 (8.1)	60.7 (6.6)
Body mass index	27.4 (4.7)	28.0 (4.7)
Smoking status		
Never	183,987 / 332,773 (55%)	1,861 / 4,043 (46%)
Previous	114,349 / 332,773 (34%)	1,790 / 4,043 (44%)
Current	34,437 / 332,773 (10%)	392 / 4,043 (9.7%)
Alcohol drinker status		
Never	10,655 / 332,773 (3.2%)	122 / 4,043 (3.0%)
Previous	10,982 / 332,773 (3.3%)	140 / 4,043 (3.5%)
Current	311,136 / 332,773 (93%)	3,781 / 4,043 (94%)
Townsend deprivation index	-1.4 (3.0)	-1.6 (3.0)

Basophil count	0.0 (0.1)	0.0 (0.1)
Eosinophil count	0.2 (0.1)	0.2 (0.1)
Lymphocyte count	1.9 (0.6)	1.9 (0.6)
Monocyte count	0.5 (0.2)	0.5 (0.2)
Neutrophil count	4.2 (1.4)	4.3 (1.4)
Overall WBC count	6.9 (1.7)	7.0 (1.8)
1n / N (%): Mean (SD)		

Table 1. Baseline characteristics of UK Biobank study sample.

As a percentage of the total WBC count based on the median values, basophils accounted for 0.3%, eosinophils 2.11%, lymphocytes 28.16%, monocytes 6.78%, and neutrophils 60.39% (Supplementary Table 12). A pair-wise correlation matrix between each WBC subtype showed a high correlation between total WBC and neutrophil count, while for the other subtypes the correlation coefficients were equal or below 0.3 (Supplementary Figure 3). Batch variables (e.g. blood sample device and sampling date), Townsend DI, and alcohol drinker status explained some of the variance in WBC count (0% to 0.66%). Depending on the WBC subtype, genetic sex explained between 0.23% to 2.93% of the variance, BMI explained between 0.14% to 2.64%, and smoking status explained between 0.44% to 3.85% (Supplementary Figure 4).

In the main analysis ("Model 1" - the minimally adjusted model), basophil count was positively associated with CRC risk (RR: 1.06, 95% CI: 1.02-1.09, P-value: 0.0005), as was monocyte (RR: 1.05, 95% CI: 1.02-1.08, P-value: 0.003) and neutrophil count (RR: 1.09, 95% CI: 1.06-1.13, P-value: 1.94E-08) (**Figure 2, Supplementary Table 13**). In "Model 2", eosinophil count was negatively associated with CRC risk (overall CRC RR: 0.96, 95% CI: 0.93-0.99, P-value: 0.022) (**Supplementary Table 13**).

Observational associations were re-computed by adding all five WBC subtype counts together. In the minimally adjusted "Model 1", eosinophil count (RR: 0.96, 95% CI: 0.93-0.99, P-value: 0.009) was associated with lower overall CRC odds, while basophil (RR: 1.04, 95% CI: 1.01-1.08, P-value: 0.008) and neutrophil count (RR: 1.08, 95% CI: 1.05-1.12, P-value: 1.92E-06) were associated with an increase in overall CRC risk (Supplementary Table 14). These results largely coincided with those from the fully adjusted "Model 2" analyses (Supplementary Table 14). All results, including those for sex-specific CRC, are available in Supplementary Table 14.




Figure 2. The relationship between WBC count and CRC risk based on UV, MV two-sample MR and cohort observational analyses. Each WBC trait is presented on the X-axis. The estimated effect is presented on the Y-axis. Point estimates were filled where the P-value was less than 0.05. Results are interpreted as ORs (95% CI) for CRC risk per 1-SD normalized increment in WBC count.

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

Discussion In this study we aimed to estimate the effects of five circulating WBC subtypes on CRC risk by using a combined genetic epidemiologic and longitudinal cohort framework. Through the aid of MVMR, we were able to assess the independent causal effect of WBC counts by adjusting for their shared genetic architecture. Taken together, the evidence across analyses suggests a potential protective effect of increased circulating eosinophil and lymphocyte count on CRC risk. Consistent with our study, Prizment et al found that eosinophil count (tertiles Q3 and Q2 vs. Q1) was negatively associated with odds of developing colon, but not of rectal cancer [19]. Similar results have been reported for other cancers; Wong et al. reported a negative trend between increasing eosinophil count quartiles and lung adenocarcinoma odds in a UKBB study [59], while a similar study looking at prostate cancer showed a negative association between eosinophil count quintiles Q3-5, as well as a per 1-SD increase in the trait (HR 0.96 vs. OR 0.93 for CRC in our analysis) [60]. Eosinophils have a well-established role in allergic disease, including asthma and allergic rhinitis [61]. Indeed, MR analyses have also reported a causal effect of eosinophil count on allergic disease [57,62] and a recent systematic review investigating the relationship between allergies and cancer reported evidence for a reduced risk of CRC in those with allergic diseases [63]. Here, our results suggest that the immune response through by eosinophils provides protection against tumour development. Indeed, in several neoplasia, including CRC,

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

eosinophils have been found to play an anti-tumourigenic role and are a source of antitumourigenic molecules, such as eosinophil-derived neurotoxin (EDN) [64,65]. Experimental studies have also found a tumour-protective effect of IgE [66]. Increased eosinophil recruitment to the CRC tumour site has also been associated with better survival, even when adjusting for the effects of CD8⁺ T-cells [13], and eosinophil-specific granule secretion of granzyme A has been linked with the killing of CRC cells [67]. In addition to eosinophil count, we also found a protective effect of lymphocyte count on CRC risk. While this was not apparent in the MR analysis, the MVMR estimates indicated lower ORs for CRC across all anatomical subsites (proximal colon cancer trended towards protective) with increased lymphocyte counts. The multivariable fully adjusted "Model 2" in the cohort analysis also indicated that there could be a negative association with CRC risk. It is not surprising that we found a protective effect of higher circulating levels of lymphocytes with CRC odds given their established role in combatting tumour development [68]. Tumourinfiltrating lymphocytes (TILs) like CD8+ T-cells help antagonise tumour growth through direct action and recruitment of other immune cells [68]. High levels of TILs were previously associated with better CRC overall survival and disease-free survival [22,68]. In support of our findings, two observational studies found higher lymphocyte counts compared to cases vs. controls a year to six months prior to CRC diagnosis [69,70]. However, these results could indicate production and recruitment of lymphocytes to the site of pre-cancerous or undetected tumours rather than a causal effect. Limitations There are several limitations to this study. With regards to the cohort analysis, only baseline blood measurements were available. This assumes that WBC counts were constant and did

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

not allow us to establish a relationship between a trend in WBC count and its relationship with CRC odds. Nevertheless, baseline WBC count measurements have previously been shown to be associated with disease risk [59,60,71,72], making their study in relation to disease development a worthwhile endeavour. Also, in the cohort analysis, incident CRC cases were defined as those diagnosed at least one year after blood sampling, in order to not diminish the number of cases to a large degree. However, as CRC develops over a long period, our cohort analysis may have not excluded all participants with undiagnosed CRC. With regards to the MR analysis, the genetic instruments used here proxied for lifetime variation of WBC count. Therefore, the MR analysis cannot be used to infer how large changes over a short timespan might affect CRC development. Regarding the MVMR method, caution should be applied when investigating traits with very weak instruments, as it cannot reliably adjust for those traits [58]. This was the case for basophil count, as the Fstatistic was estimated to be between 4.7 and 4.8 (Supplementary Table 12). Therefore, despite pointing to an increased detrimental effect compared to the main MVMR analysis, ORs derived from the weak-MVMR analysis should be interpreted with this in mind. Conclusion In summary, the results generated here provide evidence for a protective causal effect of elevated levels of circulating eosinophil and lymphocyte counts on CRC risk. Going forward, additional research is needed to disentangle the biological mechanisms and pinpoint specific pathways through which eosinophils and lymphocytes might protect against CRC development.

Availability of data and materials

- 458 Summary statistics for WBC counts were downloaded from the following website:
- 459 http://www.mhi-humangenetics.org/en/resources/. The summary-level GWAS data on
- outcomes used in this study were made available following an application to the Genetics and
- 461 Epidemiology of Colorectal Cancer Consortium (GECCO):
- 462 https://www.fredhutch.org/en/research/divisions/public-health-sciences-
- 463 <u>division/research/cancer-prevention/genetics-epidemiology-colorectal-cancer-consortium-</u>
- 464 gecco.html.

457

465

466

471

472

Contributions

- 467 AC, CJB, JH and EEV conceived the idea for the paper. AC conducted the analysis. All
- 468 authors contributed to the interpretation of the findings. AC, CJB and EEV wrote the
- 469 manuscript. All authors critically revised the paper for intellectual content and approved the
- 470 final version of the manuscript.

Funding information

- 473 AC acknowledges funding from grant MR/N0137941/1 for the GW4 BIOMED MRC DTP,
- awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research
- 475 Council (MRC)/UKRI. NJT is the PI of the Avon Longitudinal Study of Parents and Children
- 476 (Medical Research Council & Wellcome Trust 217065/Z/19/Z) and is supported by the
- 477 University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001). NJT
- acknowledges funding from the Wellcome Trust (202802/Z/16/Z). EEV, CJB, ND and NJT
- 479 acknowledge funding by the CRUK Integrative Cancer Epidemiology Programme
- 480 (C18281/A29019). NJT, EEV and CJB work in a unit funded by the UK Medical Research
- Council (MC_UU_00011/1 & MC_UU_00011/4) and the University of Bristol. EEV and
- 482 CJB are supported by Diabetes UK (17/0005587) and the World Cancer Research Fund
- The supported by Blackets on (1770000007) and the World Cameer Research Faint
- 483 (WCRF UK), as part of the World Cancer Research Fund International grant program
- 484 (IIG_2019_2009). JRH acknowledges funding by the National Cancer Institute at the U.S.
- National Institutes of Health (R21CA230486). This work was also supported by the Elizabeth
- 486 Blackwell Institute for Health Research, University of Bristol, and the Wellcome Trust
- 487 Institutional Strategic Support Fund (ISSF 204813/Z/16/Z). The funders of the study had no
- 488 role in the study design, data collection, data analysis, data interpretation or writing of the
- 489 report.

490

491

Ethics declaration

- 492 All participants provided written informed consent, and each study was approved by the
- relevant research ethics committee or institutional review board.

494 495 Consent for publication 496 All authors consented to the publication of this work. 497 498 **Competing interests** 499 The authors declare no competing interests. 500 **Supplementary information** 501 502 Additional file 1 503 Supplementary Figures. 504 Additional file 2 505 Supplementary Tables. 506 Additional file 3 507 STROBE-MR checklist. 508 Additional file 4 509 STROBE Cohort checklist. 510 Additional file 5 511 Full funding and acknowledgements details. 512 513 References 514 [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer 515 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 516 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. 517 https://doi.org/10.3322/CAAC.21492. 518 [2] Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young 519 adults in the USA: analysis of a population-based cancer registry. Lancet Public Heal 520 2019;4:e137–47. https://doi.org/10.1016/S2468-2667(18)30267-6/ATTACHMENT/EA91DB97-1C30-4C2F-B604-48BF68319153/MMC1.PDF. 521 522 Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early□onset [3] 523 colorectal cancer in young individuals. Mol Oncol 2019;13:109. https://doi.org/10.1002/1878-0261.12417. 524 525 [4] Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl 526 Oncol 2021;14:101174. https://doi.org/10.1016/J.TRANON.2021.101174. 527 [5] Chambers AC, Dixon SW, White P, Williams AC, Thomas MG, Messenger DE. 528 Demographic trends in the incidence of young onset colorectal cancer: a 529 population based study. Br J Surg 2020;107:595. https://doi.org/10.1002/BJS.11486.

- 530 [6] SEER. Surveillance, Epidemiology, and End Results (SEER) Program. 2019.
- 531 [7] Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, et al.
- Changes in colorectal cancer incidence in seven high-income countries: a population-based study. Lancet Gastroenterol Hepatol 2019;4:511–8.
- https://doi.org/10.1016/S2468-1253(19)30147-5.
- 535 [8] Hull MA. Nutritional prevention of colorectal cancer. Proc Nutr Soc 2021;80:59–64. 536 https://doi.org/10.1017/S0029665120000051.
- 537 [9] Nicholson LB. The immune system. Essays Biochem 2016;60:275–301. https://doi.org/10.1042/EBC20160017.
- 539 [10] Lee YJ, Lee HR, Nam CM, Hwang UK, Jee SH. White Blood Cell Count and the Risk of Colon Cancer. Yonsei Med J 2006;47.
- 541 [11] Wu J, Ge X, Zhu W, Zhi Q, Xu M, Duan W, et al. Values of applying white blood cell counts in the prognostic evaluation of resectable colorectal cancer. Mol Med Rep 2019;19:2330–40. https://doi.org/10.3892/MMR.2019.9844.
- 544 [12] Watt DG, Martin JC, Park JH, Horgan PG, McMillan DC. Neutrophil count is the most important prognostic component of the differential white cell count in patients undergoing elective surgery for colorectal cancer 2015;210:24–30.
- 547 [13] Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Lee JJ, Sriramarao P, et al.
 548 Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa
 549 Women's Health Study. Mod Pathol 2016;29:516–27.
 550 https://doi.org/10.1038/modpathol.2016.42.
- Rosman Y, Hornik-Lurie T, Meir-Shafrir K, Lachover-Roth I, Cohen-Engler A,
 Munitz A, et al. Changes in peripheral blood eosinophils may predict colorectal cancer
 A retrospective study. World Allergy Organ J 2022;15:100696.
 https://doi.org/10.1016/J.WAOJOU.2022.100696.
- Iijima K, Fujibayashi K, Okumura M, Sasabe N, Gunji T. Number of Eosinophils and
 Incidence of Cancer in a Japanese Population □: A Single Institution Study. Orig Artic
 Ningen Dock Int 2019;6:56–61.
- Liu Q, Luo D, Cai S, Li Q, Li X. Circulating basophil count as a prognostic marker of tumor aggressiveness and survival outcomes in colorectal cancer. Clin Transl Med 2020 91 2020;9:1–12. https://doi.org/10.1186/S40169-019-0255-4.
- Wei Y, Zhang X, Wang G, Zhou Y, Luo M, Wang S, et al. The impacts of pretreatment circulating eosinophils and basophils on prognosis of stage □-□
 colorectal cancer. Asia Pac J Clin Oncol 2018;14:e243-51.
 https://doi.org/10.1111/AJCO.12871.
- Harbaum L, Pollheimer MJ, Kornprat P, Lindtner RA, Bokemeyer C, Langner C.
 Peritumoral eosinophils predict recurrence in colorectal cancer. Mod Pathol 2015 283
 2014;28:403–13. https://doi.org/10.1038/modpathol.2014.104.
- Frizment AE, Anderson KE, Visvanathan K, Folsom AR. Inverse association of
 eosinophil count with colorectal cancer incidence: Atherosclerosis Risk in
 Communities study. Cancer Epidemiol Biomarkers Prev 2011;20:1861–4.
 https://doi.org/10.1158/1055-9965.EPI-11-0360/66619/AM/INVERSE ASSOCIATION-OF-EOSINOPHIL-COUNT-WITH.
- 573 [20] Ma W, Yang J, Li P, Lu X, Cai J. Association between allergic conditions and colorectal cancer risk/mortality: a meta-analysis of prospective studies. Sci Reports 2017 71 2017;7:1–7. https://doi.org/10.1038/s41598-017-04772-9.
- 576 [21] Yamamoto T, Kawada K, Obama K. Inflammation-Related Biomarkers for the 577 Prediction of Prognosis in Colorectal Cancer Patients. Int J Mol Sci 2021, Vol 22, 578 Page 8002 2021;22:8002. https://doi.org/10.3390/IJMS22158002.
- 579 [22] Tanio A, Saito H, Uejima C, Takaya S, Yamamoto M, Tokuyasu N, et al. A prognostic

- index for colorectal cancer based on preoperative absolute lymphocyte, monocyte, and neutrophil counts. Surg Today 2019;49:245–53. https://doi.org/10.1007/S00595-018-1728-6/TABLES/2.
- Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol 2019;106:309–22. https://doi.org/10.1002/JLB.4RI0818-311R.
- Quail DF, Amulic B, Aziz M, Barnes BJ, Eruslanov E, Fridlender ZG, et al.
 Neutrophil phenotypes and functions in cancer: A consensus statement. J Exp Med
 2022;219:39. https://doi.org/10.1084/JEM.20220011/213202.
- 588 [25] Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014;23:R89–98. 590 https://doi.org/10.1093/hmg/ddu328.
- Zheng J, Baird D, Borges M-C, Bowden J, Hemani G, Haycock P, et al. Recent
 Developments in Mendelian Randomization Studies. Curr Epidemiol Reports
 2017;4:330–45. https://doi.org/10.1007/s40471-017-0128-6.
- 594 [27] Smith GD, Ebrahim S. SEER. Surveillance, Epidemiology, and End Results (SEER) 595 Program. Int J Epidemiol 2003;32:1–22. https://doi.org/10.1093/ije/dyg070.
- 596 [28] Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30–42. https://doi.org/10.1093/ije/dyh132.
- Davies NM, Holmes M V., Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018;362:601. https://doi.org/10.1136/bmj.k601.
- [30] Carter AR, Sanderson E, Hammerton G, Richmond RC, Davey Smith G, Heron J, et
 al. Mendelian randomisation for mediation analysis: current methods and challenges
 for implementation. Eur J Epidemiol 2021 365 2021;36:465–78.
 https://doi.org/10.1007/S10654-021-00757-1.
- Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, Vanderweele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ 2021;375. https://doi.org/10.1136/BMJ.N2233.
- Chen MH, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al. Transethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5
 Global Populations. Cell 2020;182:1198-1213.e14.
 https://doi.org/10.1016/j.cell.2020.06.045.
- [33] Huyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, et al. Discovery of
 common and rare genetic risk variants for colorectal cancer. Nat Genet 2019;51:76.
 https://doi.org/10.1038/S41588-018-0286-6.
- [34] Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, et al.
 Identification of Genetic Susceptibility Loci for Colorectal Tumors in aGenome-Wide
 Meta-analysis. Gastroenterology 2013;144.
 https://doi.org/10.1053/j.gastro.2012.12.020.
- Schumacher FR, Schmit SL, Jiao S, Edlund CK, Wang H, Zhang B, et al. Genome wide association study of colorectal cancer identifies six new susceptibility loci. Nat
 Commun 2015 61 2015;6:1–7. https://doi.org/10.1038/ncomms8138.
- [36] Schmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR, et al.
 Novel Common Genetic Susceptibility Loci for Colorectal Cancer. JNCI J Natl Cancer
 Inst 2019;111:146–57. https://doi.org/10.1093/JNCI/DJY099.
- Zhang B, Jia WH, Matsuda K, Kweon SS, Matsuo K, Xiang YB, et al. Large-scale
 genetic study in East Asians identifies six new loci associated with colorectal cancer
 risk. Nat Genet 2014;46:533. https://doi.org/10.1038/NG.2985.
- 629 [38] Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-base

- platform supports systematic causal inference across the human phenome. Elife 2018;7.
- [39] Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
 imprecisely measured traits using GWAS summary data. PLoS Genet 2017;13.
 https://doi.org/10.1371/JOURNAL.PGEN.1007081.
- [40] Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am J Clin Nutr 2016;103:965–78.
 https://doi.org/10.3945/ajcn.115.118216.
- Auton A, Abecasis GR, Altshuler DM, Durbin RM, Bentley DR, Chakravarti A, et al.
 A global reference for human genetic variation. Nature 2015;526:68–74.
 https://doi.org/10.1038/nature15393.
- Wootton RE, Sallis HM. Let's call it the effect allele: a suggestion for GWAS naming conventions. Int J Epidemiol 2020;49:1734–5. https://doi.org/10.1093/IJE/DYAA149.
- Burgess S, Dudbridge F, Thompson SG. Combining information on multiple
 instrumental variables in Mendelian randomization: comparison of allele score and
 summarized data methods. Stat Med 2016;35:1880–906.
 https://doi.org/https://doi.org/10.1002/sim.6835.
- Burgess S, Thompson SG. Bias in causal estimates from Mendelian randomization studies with weak instruments. 2010.
- [45] Shim H, Chasman DI, Smith JD, Mora S, Ridker PM, Nickerson DA, et al. A
 Multivariate Genome-Wide Association Analysis of 10 LDL Subfractions, and Their
 Response to Statin Treatment, in 1868 Caucasians. PLoS One 2015;10:120758.
 https://doi.org/10.1371/JOURNAL.PONE.0120758.
- Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al.
 Guidelines for performing Mendelian randomization investigations. Wellcome Open
 Res 2020 4186 2020;4:186. https://doi.org/10.12688/wellcomeopenres.15555.2.
- Greco M F Del, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in
 Mendelian randomisation studies with summary data and a continuous outcome. Stat
 Med 2015;34:2926–40. https://doi.org/10.1002/SIM.6522.
- [48] Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512–25. https://doi.org/10.1093/ije/dyv080.
- [49] Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
 Estimator. Genet Epidemiol 2016;40:304–14.
 https://doi.org/https://doi.org/10.1002/gepi.21965.
- [50] Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian
 randomization via the zero modal pleiotropy assumption. Int J Epidemiol
 2017;46:1985–98. https://doi.org/10.1093/ije/dyx102.
- Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy
 in causal relationships inferred from Mendelian randomization between complex traits
 and diseases. Nat Genet 2018 505 2018;50:693–8. https://doi.org/10.1038/s41588-018-0099-7.
- Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of
 multivariable Mendelian randomization in the single-sample and two-sample summary
 data settings. Int J Epidemiol 2019;48:713–27. https://doi.org/10.1093/ije/dyy262.
- 53 Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12:e1001779–e1001779.


- https://doi.org/10.1371/journal.pmed.1001779.
- [54] Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK
 Biobank resource with deep phenotyping and genomic data. Nature 2018;562:203–9.
 https://doi.org/10.1038/s41586-018-0579-z.
- Simon Sheard Rob Nicholls James Froggatt AM. UK Biobank Haematology DataCompanion Document n.d.
- Burrows K, Bull CJ, Dudding T, Gormley M, Robinson T, Tan V, et al. Genome-wide
 Association Study of Cancer Risk in UK Biobank 2021.
 https://doi.org/10.5523/bris.aed0u12w0ede20olb0m77p4b9.
- Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The Allelic
 Landscape of Human Blood Cell Trait Variation and Links to Common Complex
 Disease. Cell 2016;167:1415-1429.e19. https://doi.org/10.1016/j.cell.2016.10.042.
- [58] Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic
 instruments in two-sample multivariable Mendelian randomization. Stat Med
 2021;40:5434–52. https://doi.org/10.1002/SIM.9133.
- Wong JYY, Bassig BA, Loftfield E, Hu W, Freedman ND, Ji BT, et al. White Blood
 Cell Count and Risk of Incident Lung Cancer in the UK Biobank. JNCI Cancer Spectr
 2020;4. https://doi.org/10.1093/JNCICS/PKZ102.
- [60] Watts EL, Perez-Cornago A, Kothari J, Allen NE, Travis RC, Key TJ. Hematologic
 markers and prostate cancer risk: a prospective analysis in UK Biobank. Cancer
 Epidemiol Biomarkers Prev 2020;29:1615–26. https://doi.org/10.1158/1055-9965.EPI 19-1525/70795/AM/HAEMATOLOGICAL-MARKERS-AND-PROSTATE CANCER-RISK-A.
- Henson VS, Hartl S, Barnes N, Galwey N, Van Dyke MK, Kwon N. Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. Eur Respir J 2022;59. https://doi.org/10.1183/13993003.04590-2020.
- Morrison J, Knoblauch N, Marcus JH, Stephens M, He X. Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics. Nat Genet 2020 527 2020;52:740–7. https://doi.org/10.1038/s41588-020-0631-4.
- 710 [63] Karim AF, Westenberg LEH, Eurelings LEM, Otten R, Gerth Van Wijk R. The 711 association between allergic diseases and cancer: a systematic review of the literature 712 n.d.
- 713 [64] Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone GG, Mattei F, et al.
 714 Eosinophils: The unsung heroes in cancer? vol. 7. 2018.
 715 https://doi.org/10.1080/2162402X.2017.1393134.
- 716 [65] Arnold IC, Artola-Boran M, Gurtner A, Bertram K, Bauer M, Frangez Z, et al. The
 717 GM-CSF-IRF5 signaling axis in eosinophils promotes antitumor immunity through
 718 activation of type 1 T cell responses. J Exp Med 2020;217.
 719 https://doi.org/10.1084/JEM.20190706/152117.
- Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, et al. IgE/FcεRI-mediated antigen cross-presentation by dendritic cells enhances anti-tumor immune responses. Cell Rep 2015;10:1487. https://doi.org/10.1016/J.CELREP.2015.02.015.
- [67] Legrand F, Driss V, Delbeke M, Loiseau S, Hermann E, Dombrowicz D, et al. Human
 Eosinophils Exert TNF-α and Granzyme A-Mediated Tumoricidal Activity toward
 Colon Carcinoma Cells. J Immunol 2010;185:7443–51.
 https://doi.org/10.4049/JIMMUNOL.1000446.
- Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C. The Prognostic Implications
 of Tumor Infiltrating Lymphocytes in Colorectal Cancer: A Systematic Review and
 Meta-Analysis. Sci Reports 2020 101 2020;10:1–14. https://doi.org/10.1038/s41598-

730 020-60255-4.

745 746

- Formula (19)
 Boursi B, Mamtani R, Hwang WT, Haynes K, Yang YX. A Risk Prediction Model for Sporadic CRC Based on Routine Lab Results. Dig Dis Sci 2016;61:2076–86.
 https://doi.org/10.1007/S10620-016-4081-X/TABLES/4.
- 734 [70] Goshen R, Mizrahi B, Akiva P, Kinar Y, Choman E, Shalev V, et al. Predicting the presence of colon cancer in members of a health maintenance organisation by evaluating analytes from standard laboratory records. Br J Cancer 2017 1167 2017;116:944–50. https://doi.org/10.1038/bjc.2017.53.
- Siedlinski M, Jozefczuk E, Xu X, Teumer A, Evangelou E, Schnabel RB, et al.
 Siedlinski et al White Blood Cells and Blood Pressure Indices. Circulation
 2020;141:1307. https://doi.org/10.1161/CIRCULATIONAHA.119.045102.
- Welsh C, Welsh P, Mark PB, Celis-Morales CA, Lewsey J, Gray SR, et al. Association of total and differential leukocyte counts with cardiovascular disease and mortality in the UK Biobank. Arterioscler Thromb Vasc Biol 2018;38:1415–23. https://doi.org/10.1161/ATVBAHA.118.310945.

FIGURES for "Investigating the effect of circulating immune cell counts on colorectal cancer risk"



http://dx.doi.org/10.1136/gut/nl-2020-321534); ³UK Biobank (https://doi.org/10.1038/s41586-018-0579-2)
Figure 1: Study design




Figure 2: MR and Cohort analysis of WBC count on overall colorectal cancer